阿卡迪亚（ACAD）今日盘中股价大幅下挫7.37%，引发了市场的广泛关注。
消息面上，阿卡迪亚制药近日宣布，其治疗Rett综合征的药物Trofinetide获得了欧洲药品管理局人用药品委员会（CHMP）的负面意见，公司计划正式提交重新审查的请求。尽管公司表示对该药物潜力持续有信心，但这一监管挫折仍导致投资者担忧，可能影响了药物的批准前景和市场预期，从而拖累股价。
阿卡迪亚制药致力于为Rett综合征患者群体寻求新的治疗选择，但CHMP的负面意见通常被视为关键监管障碍，可能对公司的短期业绩和长期增长计划构成挑战。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.